Synergy Pharmaceuticals Inc (NASDAQ:SGYP) impressed Rodman & Renshaw analyst Ram Selvaraju with the announcement yesterday evening that the biotech has attained “a milestone …
Analysts are offering their two cents on biotech firms Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP).
As both earnings and election season are coming to a close, analysts are chiming in with varied expectations for three biotech players: Valeant …
Yesterday, DURECT Corporation’s (NASDAQ:DRRX) licensee Pain Therapeutics announced that it had received a complete response letter (CRL) from the FDA for the resubmitted …
As of the end of August 2016, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) competitor Allergan has changed the language in its product label for Linzess, …
Yesterday, Biocept Inc (NASDAQ:BIOC) announced news of solidifying a new agreement with Teneovita Medical Innovations for a full distribution range of liquid biopsy testing …
On Monday, biotech firm Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported second-quarter financial results as well as declared completion of over 95% for patient enrollment …
Rodman & Renshaw analyst Ram Selvaraju weighed in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) after the drug maker released its second-quarter results and reaffirmed its …
On August 1st, biotech firm DURECT Corporation (NASDAQ:DRRX) released its second quarter financial results for this year. In reaction, Rodman & Renshaw analyst …
Following what is “clearly a disappointing setback in a month that to date had proved to be one of positive surprises for the …
